Ontology highlight
ABSTRACT:
SUBMITTER: Byun DJ
PROVIDER: S-EPMC5629093 | biostudies-literature | 2017 Apr
REPOSITORIES: biostudies-literature
Byun David J DJ Wolchok Jedd D JD Rosenberg Lynne M LM Girotra Monica M
Nature reviews. Endocrinology 20170120 4
Advances in cancer therapy in the past few years include the development of medications that modulate immune checkpoint proteins. Cytotoxic T-lymphocyte antigen 4 (CTLA4) and programmed cell death protein 1 (PD1) are two co-inhibitory receptors that are expressed on activated T cells against which therapeutic blocking antibodies have reached routine clinical use. Immune checkpoint blockade can induce inflammatory adverse effects, termed immune-related adverse events (IRAEs), which resemble autoi ...[more]